Nomura Holdings
PTGX icon

Nomura Holdings’s Protagonist Therapeutics PTGX Stock Holding History

Nomura Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,000
Closed -$2.76M – 2038
2025
Q2 		$2.76M Buy
+50,000
New +$2.4M 0.01% 749

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Nomura Holdings's PTGX Position: Q1 2026 in Review

Nomura Holdings reduced its Protagonist Therapeutics (PTGX) stake by 40% in Q1 2026, selling an estimated $624K and leaving 10,479 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1120.

Nomura Holdings first reported a position in PTGX in Q3 2024 and has held it in 4 quarters since. The position peaked at $1.53M in Q4 2025. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Nomura Holdings held 10,479 shares of Protagonist Therapeutics worth $1.1M as of Q1 2026.
  • Nomura Holdings sold 7,042 Protagonist Therapeutics shares in Q1 2026, an estimated $624K.
  • Protagonist Therapeutics made up ﹤0.01% of Nomura Holdings's portfolio in Q1 2026, its #1120 holding.
  • Nomura Holdings first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Nomura Holdings's Protagonist Therapeutics position peaked at $1.53M in Q4 2025.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.